Valeant Has Another Leg Lower After Bad Q3 Report

Valeant Pharmaceuticals Intl Inc VRX shares are trading lower by $3.70 at $15.43 in Tuesday's session. The catalyst for sharp decline is a Q3 miss of $0.20 along with a slight miss for revenues. The company lowered FY 2016 EPS and revenues.

The EPS cut was of most significance, as it was lowered from a range of $6.60-$7.00 to $5.30-$5.50 range.

After panic-selling off the open, the issue bottomed $0.22 off its opening print of $13.99 at $13.77 and immediate began to rebound. That low coincides with its May 2010 low of $13.56.

Since making that low, it has continued to make highs for the session, with the current one standing at $15.76. In order to reach the lower-end of Monday's range, it would need to reach $18.75.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: TechnicalsIntraday UpdateMoversTrading Ideas
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!